| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Priority Reports |
Departments of 1 Obstetrics and Gynecology and 2 Laboratory Medicine and Pathology, Mayo Clinic and Foundation, Rochester, Minnesota
Requests for reprints: William A. Cliby, Department of Obstetrics and Gynecology, Mayo Clinic and Foundation, 1317 Guggenheim, 200 1st Street, Southwest Rochester, MN 55905. Phone: 507-266-9323; Fax: 507-266-9300; E-mail: Cliby.william{at}mayo.edu.
ATR (ataxia telangiectasia and Rad3-related) function is necessary for the proper response to commonly used chemotherapeutic agents. Heterozygous truncating mutations in exon 10 of the ATR gene have been described in numerous cancers exhibiting microsatellite instability. We show that truncating mutations of ATR are capable of acting in a dominant-negative manner to abrogate ATR-dependent Chk1 phosphorylation and cell-cycle arrests after DNA damage. In addition, endometrial cell lines harboring ATR mutations are defective for ATR-dependent responses. These findings imply that ATR mutations play an important role in the development and clinical behavior of a subset of microsatellite instabilitypositive endometrial, colon, and stomach cancers.
This article has been cited by other articles:
![]() |
M. J. Jardim, Q. Wang, R. Furumai, T. Wakeman, B. K. Goodman, and X.-F. Wang Reduced ATR or Chk1 Expression Leads to Chromosome Instability and Chemosensitization of Mismatch Repair-deficient Colorectal Cancer Cells Mol. Biol. Cell, September 1, 2009; 20(17): 3801 - 3809. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Zighelboim, A. P. Schmidt, F. Gao, P. H. Thaker, M. A. Powell, J. S. Rader, R. K. Gibb, D. G. Mutch, and P. J. Goodfellow ATR Mutation in Endometrioid Endometrial Cancer Is Associated With Poor Clinical Outcomes J. Clin. Oncol., July 1, 2009; 27(19): 3091 - 3096. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. A. Lewis, K. K. Lilly, E. A. Reynolds, W. P. Sullivan, S. H. Kaufmann, and W. A. Cliby Ataxia telangiectasia and rad3-related kinase contributes to cell cycle arrest and survival after cisplatin but not oxaliplatin Mol. Cancer Ther., April 1, 2009; 8(4): 855 - 863. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Chanoux, B. Yin, K. A. Urtishak, A. Asare, C. H. Bassing, and E. J. Brown ATR and H2AX Cooperate in Maintaining Genome Stability under Replication Stress J. Biol. Chem., February 27, 2009; 284(9): 5994 - 6003. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Black, R. A. Soslow, D. A. Levine, C. Tornos, S. C. Chen, A. J. Hummer, F. Bogomolniy, N. Olvera, R. R. Barakat, and J. Boyd Clinicopathologic Significance of Defective DNA Mismatch Repair in Endometrial Carcinoma J. Clin. Oncol., April 10, 2006; 24(11): 1745 - 1753. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |